Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medical Ikkou Group CoTSE:3353 +0.14%63 3-Year ROIIC % is 8.44 as of Feb. 2026, which is 110% above its 10-year median of 4.02. GuruFocus rates TSE:3353 with a GF Score™ of 63/100 and a GF Value™ of 円3,551.41 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 531 Conglomerates companies, Medical Ikkou Group Co ranks better than 67.23% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Medical Ikkou Group Co's 3-Year ROIIC % for the quarter that ended in Feb. 2026 was 8.44%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Medical Ikkou Group Co's 3-Year ROIIC % or its related term are showing as below:
TSE:3353's 3-Year ROIIC % is ranked better than 67.23% of 531
companies
in the Conglomerates industry
Industry Median: 1.62
vs TSE:3353: 8.44
Medical Ikkou Group Co (TSE:3353) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Medical Ikkou Group Co 3-Year ROIIC % Related Terms
Medical Ikkou Group Co 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Medical Ikkou Group Co's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Conglomerates subindustry, Medical Ikkou Group Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Ikkou Group Co 3-Year ROIIC % vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, Medical Ikkou Group Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Medical Ikkou Group Co's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Medical Ikkou Group Co (TSE:3353) has a 3-Year ROIIC % of 8.44 as of Feb. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Medical Ikkou Group Co and its competitors. This is 110% above median its historical median of 4.02. According to the industry distribution chart, Medical Ikkou Group Co ranks #174 out of 531 companies in the Conglomerates industry, placing it in the top 32.8%.
Is Medical Ikkou Group Co's 3-Year ROIIC % too high?
Medical Ikkou Group Co's current 3-Year ROIIC % of 8.44 is 110% above median its 10-year median of 4.02. The Conglomerates industry median 3-Year ROIIC % is 1.62. Medical Ikkou Group Co's value of 8.44 is 421% above this industry median. Based on the distribution chart, Medical Ikkou Group Co ranks #174 out of 531 companies in the Conglomerates industry, which is above the industry midpoint. Overall, Medical Ikkou Group Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Ikkou Group Co's 3-Year ROIIC % compare to HON and MMM?
According to the Conglomerates industry distribution chart, Medical Ikkou Group Co ranks #174 out of 531 companies for 3-Year ROIIC %. This puts Medical Ikkou Group Co in the upper half of its industry. The industry median 3-Year ROIIC % is 1.62. Medical Ikkou Group Co's value of 8.44 is 421% above this benchmark. While the company's 10-year median is 4.02 vs. the industry median of 1.62, Medical Ikkou Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Conglomerates company?
The median 3-Year ROIIC % among Conglomerates companies is 1.62, based on 531 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Ikkou Group Co's current 3-Year ROIIC % of 8.44 is 421% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Medical Ikkou Group Co and its competitors. For the Conglomerates industry, the median 3-Year ROIIC % is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Ikkou Group Co's current 3-Year ROIIC % is 8.44, which is 110% above median its own 10-year median of 4.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Ikkou Group Co stock overvalued right now?
Based on GuruFocus' analysis, Medical Ikkou Group Co (TSE:3353) is currently considered Modestly Undervalued. The stock's GF Value™ is 円3,551.41, compared to a current price of 円2,830.00 — trading 20.3% below its estimated fair value. The current 3-Year ROIIC % is 8.44, which is 110% above median its 10-year median of 4.02 and 421% above the Conglomerates industry median of 1.62. Medical Ikkou Group Co's overall GF Score™ is 63/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Medical Ikkou Group Co (TSE:3353), the current 3-Year ROIIC % is 8.44 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Ikkou Group Co (TSE:3353) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Ikkou Group Co stock appears to be undervalued.
The current stock price of 円2,830.00 is trading 20.3% below its estimated GF Value™ of 円3,551.41.
GuruFocus considers Medical Ikkou Group Co to be Modestly Undervalued.
Key valuation signals for TSE:3353:
3-Year ROIIC %: 8.44 (110% above median its 10-year median of 4.02)
GF Value™: 円3,551.41 vs. price of 円2,830.00 (20.3% below fair value)
Industry Position: 421% above the Conglomerates median (#174 of 531)
No single metric tells the full story. See the TSE:3353 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Ikkou Group Co Ltd is engaged in Dispensing pharmacy business, healthcare business, pharmaceutical wholesale business, real estate business, and investment business.
63GF Score
Get the complete analysis for TSE:3353
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3353 has been successfully added to your 
